同期推量调强放疗联合化疗治疗鼻咽癌的近期疗效观察

目的研究同期推量调强放射治疗（SIB—IMRT）配合同期化疗对晚期鼻咽癌的疗效以及对正常组织的保护和不良反应。方法对30例鼻咽癌初治患者行鼻咽和全颈及锁骨上全程SIB—IMRT，肿瘤靶区授予处方剂量68Gy／30次。放疗期间每周1次化疗，顺铂（DDP）40mg／m^2。结果治疗计划结果显示，覆盖鼻咽计划肿瘤靶区（PGTV）1D。的平均剂量为70．48Gy，平均体积为98．5％；PGTV1、PGTV2、计划淋巴结转移灶靶区（PCTV）1和PCTV2的平均剂量分别为70．8、66．4、62．3和54．8Gy。皮肤、黏膜、涎腺和咽的Ⅲ度急性不良反应仅发生在少数病例中，分别占33％、10．0％、6．6％；血液学不良反应主要为Ⅰ～Ⅱ度白细胞减少，对症处理后均能顺利完成疗程。患者中位随访期6．5（4—10）个月，局部无进展生存率100％。结论SIB—IMRT在初治晚期鼻咽癌病例均可获得理想的剂量分布，正常组织可得到很好的保护，不良反应可以耐受，临床疗效满意。

The Short-term clinical observation of SIB-IMRT in locally advanced nasopharyngeal carcinoma

Objective To evaluate the feasibility , toxicity and clinical efficacy of intensity-modulated radiotherapy using the simultaneous integrated boost (SIB- IMRT) and concurrent chemotherapy for advanced nasopharyngeal carcinoma. Methods Thirty nsopharyngeal carcinoma were treated with full course IMRT including nasopharynx and full neck to supraclavicle. The radiotherapy dosage is 68 Gy to the target. Concurrent chemotherapy was given, and the regimen was DDP 40 mg/m2/weekly.Results The mean dose of covering gross tumor volume(PGTV) (D95) in the nasopharynx was 70.48 Gy, and the mean volume of PGTV1 receiving the 95 % dose(V95) was 98. 46 %. The mean dose of PGTV1, PGTV2, PCTV1 and PCTV2 in the targets were 70.8 Gy, 66.4 Gy, 62.3 Gy and 54.8 Gy. According to the evaluation, the acute skin,mucositis and salivary toxicity with grade Ⅲ in those patients were 3.3 %, 10 %, 6.6 %. The patients developed different blood toxicity, but didn't affect their treatment. The median follow-up time was 6.5 months, and disease free survival rate was 100 %. Conclusion SIB-IMRT yields well dose distribution and acceptable toxicity in advanced stage nasopharyngeal carcinoma. The preliminary clinical result is encouraging.